Domestic new preparations will present explosive development, CRO enterprises or meet the opportunity.

"
Pharmaceutical Network Market Analysis" Compared with traditional dosage forms, the new formulation has greater clinical advantages, can improve drug compliance, improve drug efficacy, reduce drug side effects, fill the drug gap and prevent drug abuseIn recent years, with the continuous improvement of drug safety requirements, as well as the continuous deepening of domestic research on new formulations, the market share of innovative agents is constantly increasing, causing high concern in the industrydata show that over the past decade, the global growth rate of new formulations has reached a compound annual growth rate of more than 10%, leading the average growth of the pharmaceutical industryAt present, the utilization rate of new formulations in China is less than 5%, far below the global average, so the market development prospects are broadindustry analysis that, with the continuous upgrading of domestic pharmaceutical consumption, as well as the aging of the population, the continuous improvement of the social security system and the continuous development of pharmaceutical science and technology, the use of new agents or trend, China's new formulation market will show explosive developmentin this blue sea of markets, large multinational pharmaceutical companies because of technological and capital advantages to obtain a near-monopoly positionIn the domestic "imitation drug" era gradually exited the background, enterprises gradually to the new drug innovation model conversion, preparation innovation has also become a lot of small and medium-sized enterprises to improve competitiveness of an important directionThis will also bring a large number of CRO enterprises to a good development opportunitiescurrently, A-share CRO listed enterprises have as many as 14, the national CRO enterprises more than 1000, most of the CRO enterprises have "preparation innovation." The more typical CRO listed enterprises such as the drug Mingkang and so on by the industry's attention and favordrug Mingkang is a leading enterprise in the CRO industryIts drug development services, which include one-stop services ranging from pre-prescription research, preparation development, supporting analytical support and the production of clinical trial preparations, and drug registration services, help customers quickly move NCE from the preclinical research phase to the NDA declaration phase, including the process of preparation developmentit is understood that since the completion of the integration of the preparation development services business in 2019, the company has provided CMC integrated service strategy of the whole industrial chain has achieved remarkable results, and the preparation development business revenue has also been growing rapidlyDuring the signing of 52 service projects, and through the eCTD way, for many domestic and foreign partners successfully fdaIND declaration, FDA license, access to clinical researchin December 2019, pharmaceutical Mingkang started construction of Wuxi Heye Pharmaceutical synth drug preparation development services and preparation production phase 1 project In addition to commercial production services, the future Wuxi site will also provide prescription drug development for solid and sterile preparations, as well as clinical drug production services Hequan Pharmaceutical sane pharmaceutical industry is the main small molecule CMO business carrier of the drug Mingkang, the performance growth rate in recent years basically maintained at more than 20%, the five-year compound growth rate of 26.26% Financial data show that in 2017, total pharmaceutical operating income was RMB2,189 million, up 24.12% YoY At present MAH is in a large number of pilot, covering the preparation business CMO company will first receive MAH policy dividends, the first phase of the project to introduce international solid preparation production, packaging line, has been put into production and for customers around the world to provide new drug preparation services at the same time, according to the financing plan announced by the drug Mingkang, it is proposed to issue no more than 75 million shares of shares to no more than 35 specific investors in the A-shares, raising a total amount of not more than 6,528 million yuan, the fund-raising purposes include the use of new drug preparation sydments in Wuxi, the pharmaceutical product development services and preparation production projects and the global research and development center and supporting projects In this regard, the industry believes that the future of the drug Mingkang on the "preparation development" of the importance will also continue to rise.